The DOI matches its Crossref record; 33 of the 37 references it cites were found in a registry or an index.
The pharmacology of psilocybin
Abstract
Psilocybin (4‐phosphoryloxy‐N,N‐dimethyltryptamine) is the major psychoactive alkaloid of some species of mushrooms distributed worldwide.These mushrooms represent a growing problem regarding hallucinogenic drug abuse. Despite its experimental medical use in the 1960s, only very few pharmacological data about psilocybin were known until recently. Because of its still growing capacity for abuse and the widely dispersed data this review presents all the available pharmacological data about psilocybin.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Compared to other psychedelics such as psilocybin (Holze: 5.6 ± 2.2, 6.5 ± 2.4; Ley: 4.9 ± 1.7; Passie 3–6 h) or LSD (Holze: 9.3 ± 3.2, 11 ± 3.7; Ley: 8.2 ± 3.1; Passie: 9–12 h) (39, 76–78), the overall experience duration of combined DMT/HAR with this specific administration protocol (3–4 h) is shorter.”
From Potential therapeutic effects of an ayahuasca-inspired N,N-DMT and harmine formulation: a controlled trial in healthy subjects (2024) · cites this paper as [39]
Citations
Cites
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A., Vogel, H., & Hell, D. (1998) · NeuroReport · doi:10.1097/00001756-199812010-00024 · Cited by 1,018
Serotonin-dopamine interaction and its relevance to schizophrenia
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.4.466 · Cited by 823
Vollenweider, F. (1997) · Neuropsychopharmacology · doi:10.1016/s0893-133x(96)00246-1 · Cited by 444
Vollenweider, F. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00108-0 · Cited by 305
Grinker, R. R. (1960) · Archives of General Psychiatry · doi:10.1001/archpsyc.1960.03590120120017 · Cited by 269
Hasler, F., Bourquin, D., Brenneisen, R., Bär, T., & Vollenweider, F. X. (1997) · Pharmaceutica Acta Helvetiae · doi:10.1016/s0031-6865(97)00014-9 · Cited by 232
Psilocybin und Psilocin, zwei psychotrope Wirkstoffe aus mexikanischen Rauschpilzen
Hofmann, A., Heim, R., Brack, A., Kobel, H., Frey, A., Ott, H., Petrzilka, T., & Troxler, F. (1959) · Helvetica Chimica Acta · doi:10.1002/hlca.19590420518 · Cited by 224
Gouzoulis-Mayfrank, E. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(98)00089-x · Cited by 219
Differential interactions of indolealkylamines with 5-hydroxytryptamine receptor subtypes
Mckenna, D. J., Repke, D. B., Lo, L., & Peroutka, S. J. (1990) · Neuropharmacology · doi:10.1016/0028-3908(90)90001-8 · Cited by 192
Creese, I., Burt, D. R., & Snyder, S. H. (1975) · Life Sciences · doi:10.1016/0024-3205(75)90118-6 · Cited by 169
Research works printed but not linked: 11
- Pierrot M, 2000, Intoxications par champignons hallucinogenes, Ann Med Interne (Paris, 151, BB16
- Leuner H., 1981, Halluzinogene
- Passie T., 1995, Psilocybin in der modernen Psychotherapie, Curare, 18, 131
- 10.1002/hlca.19590420518 · DOI · Paper page
- Fonseca JS, 1965, Neuro‐psychopharmacology, 315
- Quetin AM., 1960, La Psilocybine en psychiatrie clinique et experimentale
- Hidalgo W, 1960, Estudio comparativo psicofisiologico de la mescalina, dietilamida del acido D‐lysergico y psilocibina, Acta Med Venezolana, 8, 56
- Delay J, 1958, Les champignons hallucinognes du mexique, 287
- Brown FC., 1972, Hallucinogenic drugs
- Laatsch H., 1996, Maria Sabina‐Botin der heiligen Pilze, 193
- Aghajanian GK., 1994, Current status and perspectives of hallucinogens, 27
Cited by
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
“sergic acid diethylamide (LSD), with psilocybin considered to be more strongly visual, less emotionally intense, more euphoric, and with fewer panic reactions and less chance of paranoia than LSD.(17,18) Recent clinical examinations of psilocybin have indicated that it is not hazardous to physical health.”
BackgroundHuman hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
“…et al., 2007), hallucinogen pharmacokinetics and metabolism (Hasler, et al., 1997, 2002), model psychosis (Vollenweider, et al., 1997, 1998, 1999, 2007; Gouzoulis-Mayfrank, et al., 1998a; Vollenweider and Geyer, 2001; Gouzoulis-Mayfrank, et al., 2005, 2006), and, recently in our…”
Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression
Goodwin, G. M., Aaronson, S. T., Alvarez, O., Arden, P. C., Baker, A., Bennett, J. C., Bird, C., Blom, R. E., Brennan, C., Brusch, D., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206443 · Cited by 1,167
“Any severe adverse event 2 (3) 3 (4) 0”
BackgroundSafety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder
Moreno, F. A., Wiegand, C. B., Taitano, E. K., & Delgado, P. L. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n1110 · Cited by 789
“or 100 to 315 μg/kg are considered safe and able to induce a quantifiable psychedelic experience that lasts, depending on the dose, from 3 to 8 hours.(20,21) Given a large first-pass metabolism in which psilocybin is converted primarily to psilocin, the latter may actually be responsible for the psychotropic effects o…”
BackgroundPsychedelics and Psychedelic-Assisted Psychotherapy
Reiff, C. M., Richman, E. E., Nemeroff, C. B., Carpenter, L. L., Widge, A. S., Rodriguez, C. I., Kalin, N. H., McDonald, W. M., & and the Work Group on Biomarkers and Novel Treatments, A. D. O. T. A. P. A. C. O. R. (2020) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2019.19010035 · Cited by 649
Metadata
- Authors
- Passie, T., Seifert, J., Schneider, U., & Emrich, H. M.
- Affiliations
- Medizinische Hochschule Hannover (DE)
- Corresponding author
- Passie, Torsten
- ORCID
- Passie, Torsten
- Venue
- Addiction Biology
- Publisher
- Wiley
- Published
- 2002-10
- Volume
- 7
- Issue
- 4
- Pages
- 357-364
- ISSN
- 1355-6215 (ISSN-L)
- 1369-1600
- OpenAlex
- W2154105276
- Cited by
- 465
- References
- 37
- Citations by year
- 2026: 33 · 2025: 44 · 2024: 51 · 2023: 58 · 2022: 67 · 2021: 35 · 2020: 24 · 2019: 17 · 2018: 21 · 2017: 15 · 2016: 22 · 2015: 14 · 2014: 11 · 2013: 10 · 2012: 10
- FWCI
- 0.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Addiction Biology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Forensic Toxicology and Drug Analysis
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Alkaloids: synthesis and pharmacology
- Keywords
- psilocybin, tryptamine alkaloids, hallucinogens, mushroom toxins, pharmacology, psychoactive substances
- MeSH terms
- Agaricales, Animals, Brain, Hallucinogens, Humans, Psilocybin, Serotonin, Somatoform Disorders, Receptors, Presynaptic, Controlled Clinical Trials as Topic, Substance-Related Disorders, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The pharmacology of psilocybin. https://app.cochat.ai/papers/10.1080/1355621021000005937
- The paper
- Passie, T., Seifert, J., Schneider, U., & Emrich, H. M. (2002). The pharmacology of psilocybin. Addiction Biology. https://doi.org/10.1080/1355621021000005937
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.